Wells Fargo analyst David Maris maintained a Hold rating on Mylan Inc (NASDAQ: MYL) today. The company’s shares closed yesterday at $38.52.
According to TipRanks.com, Maris has currently no stars on a ranking scale of 0-5 stars, with an average return of -4.3% and a 40.9% success rate. Maris covers the Healthcare sector, focusing on stocks such as Bausch Health Companies Inc, Amphastar Pharmaceuticals, and Kala Pharmaceuticals Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Mylan Inc with a $48 average price target, which is a 24.6% upside from current levels. In a report issued on August 8, Cantor Fitzgerald also reiterated a Hold rating on the stock with a $41 price target.
.
See today’s analyst top recommended stocks >>
Based on Mylan Inc’s latest earnings release for the quarter ending June 30, the company reported a quarterly net profit of $37.5 million. In comparison, last year the company had a net profit of $297 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Mylan NV is a pharmaceutical healthcare company. The firm engages in the development, license, manufacture, market and distribution of generic, branded generic and specialty pharmaceutical products. It operates through the following geographical segments: North America, Europe, Rest of World, and Corporate or Other.
